Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Who mec for potential drug interactions

162 views

Published on

  • Be the first to comment

  • Be the first to like this

Who mec for potential drug interactions

  1. 1. 7/20/2014 WHO MEC for potential drug interactions http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F54244&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 1/2 Official reprint from UpToDate®  www.uptodate.com ©2014 UpToDate® World Health Organization medical eligibility for contraceptive use: Drug interactions Condition COC CIC P/R POP DMPA NET­ EN LNG/ETG Implants Cu­IUD LNG­IUD Drugs which affect liver enzymes Rifampicin or rifabutin 3 2 3 3 DMPA 1 NET­EN 2 2 1 1 Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) 3 2 3 3 DMPA 1 NET­EN 2 2 1 1 Lamotrigine 3 3 3 1 1 1 1 1 Antimicrobials (excluding rifampicin) Broad spectrum antibiotics 1 1 1 1 1 1 1 1 Antifungals and Antiparasites 1 1 1 1 1 1 1 1 Antiretroviral therapy Nucleoside reverse transcriptase inhibitors 1 1 1 1 DMPA 1 NET­EN 1 1 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2
  2. 2. 7/20/2014 WHO MEC for potential drug interactions http://www.uptodate.com.myaccess.library.utoronto.ca/contents/image?imageKey=OBGYN%2F54244&rank=1~150&search=contracep%C3%A7%C3%A3o&source=image_view&view=print&topicKey=OBGYN/5459&source=se… 2/2 Non­nucleoside reverse transcriptase inhibitors 2 2 2 2 DMPA 1 NET­EN 2 2 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2 Ritonavir­boosted protease inhibitors 3 3 3 3 DMPA 1 NET­EN 2 2 Initiation: 2/3 Continuation: 2 Initiation: 2/3 Continuation: 2 WHO comments: Although the interaction of rifampicin or rifabutin with POPs, NET­EN and LNG/ETG implants is not harmful to women, it is likely to reduce the effectiveness of POPs, NET­EN and LNG/ETG implants. Use of other contraceptives should be encouraged for women who are long­term users of any of these drugs.Whether increasing the hormone dose of POPs alleviates this concern remains unclear. Use of DMPA is a Category 1 because its effectiveness is not decreased by the use of rifampicin or rifabutin. 1: A condition for which there is no restriction for the use of the contraceptive method. 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks. 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method. 4: A condition which represents an unacceptable health risk if the contraceptive method is used. COC: low­dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen­only pill; DMPA: depot medroxyprogesterone acetate; NET­EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu­IUD: copper intrauterine device; LNG­IUD: levonorgestrel­releasing IUDs; E­IUD: copper­IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness­based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization. Reproduced with permission from: Medical Eligibility Criteria for Contraceptive Use ­ 3rd Ed. Available at: http://www.who.int/reproductive­ health/publications/mec/summary.html. Copyright ©2006 World Health Organization. Revised from: Medical Eligibility Criteria for Contraceptive Use, 2008 update. Available at: http://www.who.int/reproductive­health/publications/mec/. Graphic 54244 Version 2.0

×